Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

被引：11
作者：
Stefanoudakis, Dimitrios [1 ]
Frountzas, Maximos [1 ]
Schizas, Dimitrios [2 ]
Michalopoulos, Nikolaos V. [1 ]
Drakaki, Alexandra [3 ]
Toutouzas, Konstantinos G. [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Hippocrat Gen Hosp, Sch Med, Propaedeut Dept Surg 1, Athens 11527, Greece
[2] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Sch Med, Dept Surg 1, Athens 11527, Greece
[3] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA
来源：
CURRENT ISSUES IN MOLECULAR BIOLOGY | 2024年 / 46卷 / 04期
关键词：
TP53; CDKN2A; SMAD4; KRAS; pancreatic cancer; PDAC; tumor suppressor genes; tumor markers; biomarkers; targeted therapy; K-RAS; DUCTAL ADENOCARCINOMA; CLINICAL-SIGNIFICANCE; PERSONALIZED THERAPY; MUTANT TP53; WILD-TYPE; EXPRESSION; MUTATIONS; P53; GENES;
D O I：
10.3390/cimb46040177
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The present review demonstrates the major tumor suppressor genes, including TP53, CDKN2A and SMAD4, associated with pancreatic cancer. Each gene's role, prevalence and impact on tumor development and progression are analyzed, focusing on the intricate molecular landscape of pancreatic cancer. In addition, this review underscores the prognostic significance of specific mutations, such as loss of TP53, and explores some potential targeted therapies tailored to these molecular signatures. The findings highlight the importance of genomic analyses for risk assessment, early detection and the design of personalized treatment approaches in pancreatic cancer. Overall, this review provides a comprehensive analysis of the molecular intricacies of pancreatic tumors, paving the way for more effective and tailored therapeutic interventions.
引用
收藏
页码：2827 / 2844
页数：18
相关论文
共 126 条
  • [1] Abrams Stephen L., 2018, Advances in Biological Regulation, V69, P16, DOI 10.1016/j.jbior.2018.06.002
  • [2] The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
    Ahmed, Sunjida
    Bradshaw, Azore-Dee
    Gera, Shweta
    Dewan, M. Zahidunnabi
    Xu, Ruliang
    [J]. JOURNAL OF CLINICAL MEDICINE, 2017, 6 (01):
  • [3] KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
    Amintas, Samuel
    Fernandez, Benjamin
    Chauvet, Alexandre
    Chiche, Laurence
    Laurent, Christophe
    Belleannee, Genevieve
    Marty, Marion
    Buscail, Etienne
    Dabernat, Sandrine
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Genomic analyses identify molecular subtypes of pancreatic cancer
    Bailey, Peter
    Chang, David K.
    Nones, Katia
    Johns, Amber L.
    Patch, Ann-Marie
    Gingras, Marie-Claude
    Miller, David K.
    Christ, Angelika N.
    Bruxner, Tim J. C.
    Quinn, Michael C.
    Nourse, Craig
    Murtaugh, L. Charles
    Harliwong, Ivon
    Idrisoglu, Senel
    Manning, Suzanne
    Nourbakhsh, Ehsan
    Wani, Shivangi
    Fink, Lynn
    Holmes, Oliver
    Chin, Vencssa
    Anderson, Matthew J.
    Kazakoff, Stephen
    Leonard, Conrad
    Newell, Felicity
    Waddell, Nick
    Wood, Scott
    Xu, Qinying
    Wilson, Peter J.
    Cloonan, Nicole
    Kassahn, Karin S.
    Taylor, Darrin
    Quek, Kelly
    Robertson, Alan
    Pantano, Lorena
    Mincarelli, Laura
    Sanchez, Luis N.
    Evers, Lisa
    Wu, Jianmin
    Pinese, Mark
    Cowley, Mark J.
    Jones, Marc D.
    Colvin, Emily K.
    Nagrial, Adnan M.
    Humphrey, Emily S.
    Chantrill, Lorraine A.
    Mawson, Amanda
    Humphris, Jeremy
    Chou, Angela
    Pajic, Marina
    Scarlett, Christopher J.
    [J]. NATURE, 2016, 531 (7592) : 47 - +
  • [5] Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
    Bardeesy, Nabeel
    Cheng, Kuang-hung
    Berger, Justin H.
    Chu, Gerald C.
    Pahler, Jessica
    Olson, Peter
    Hezel, Aram F.
    Horner, James
    Lauwers, Gregory Y.
    Hanahan, Douglas
    DePinho, Ronald A.
    [J]. GENES & DEVELOPMENT, 2006, 20 (22) : 3130 - 3146
  • [6] CDKN2A germline mutations in familial pancreatic cancer
    Bartsch, DK
    Sina-Frey, M
    Lang, S
    Wild, A
    Gerdes, B
    Barth, P
    Kress, R
    Grützmann, R
    Colombo-Benkmann, M
    Ziegler, A
    Hahn, SA
    Rothmund, M
    Rieder, H
    [J]. ANNALS OF SURGERY, 2002, 236 (06) : 730 - 737
  • [7] Beganovic S, 2009, BOSNIAN J BASIC MED, V9, pS17
  • [8] COMPARATIVE-ANALYSIS OF MUTATIONS IN THE P53 AND K-RAS GENES IN PANCREATIC-CANCER
    BERROZPE, G
    SCHAEFFER, J
    PEINADO, MA
    REAL, FX
    PERUCHO, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (02) : 185 - 191
  • [9] DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma
    Biankin, AV
    Morey, AL
    Lee, CS
    Kench, JG
    Biankin, SA
    Hook, HC
    Head, DR
    Hugh, TB
    Sutherland, RL
    Henshall, SM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) : 4531 - 4542
  • [10] Genome Profiling of Pancreatic Adenocarcinoma
    Birnbaum, David J.
    Adelaide, Jose
    Mamessier, Emilie
    Finetti, Pascal
    Lagarde, Arnaud
    Monges, Genevieve
    Viret, Frederic
    Goncalves, Anthony
    Turrini, Olivier
    Delpero, Jean-Robert
    Iovanna, Juan
    Giovannini, Marc
    Birnbaum, Daniel
    Chaffanet, Max
    [J]. GENES CHROMOSOMES & CANCER, 2011, 50 (06) : 456 - 465
12345678910